Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.
Anoro Ellipta should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD, or as rescue therapy for the treatment of acute episodes of ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (lse/nyse:GSK) and Theravance, Inc. THRX +1.96% today announced that Anoro™ Ellipta® ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
GlaxoSmithKline’s (GSK) new chronic obstructive pulmonary disease (COPD) has moved closer to EU registration after being recommended for approval by the Committee for Medicinal Products for Human Use ...
Improvement in lung function was measured using FEV1 (forced expiratory volume in one second). FEV1 is a measurement of how much air you can force out of your lungs in one second. Higher FEV1 values ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback